Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 4

Concentrated Bone Marrow Aspirate in Revision ACL Reconstruction

NCT06311513 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this pilot randomized clinical trial is to look into the efficacy of concentrated bone marrow aspirate (cBMA) in improving post traumatic osteoarthritis (PTOA) symptoms in patients undergoing revision anterior cruciate ligament reconstruction surgery. The main questions it aims to answer are whether clinical outcomes, such as pain, are improved in patients who get cBMA with surgery, if there is a change in circulating markers of inflammation and what part of the cellular and molecular composition of cBMA may explain its effects.

Interventions

  • BIOLOGICAL Concentrated Bone Marrow Aspirate Injection
  • PROCEDURE Sham Incision
  • PROCEDURE Revision Anterior Cruciate Ligament Reconstruction

Study Locations (2)

Georgia

  • Emory Orthopaedics & Spine Center — Atlanta

New York

  • Hospital for Special Surgery — New York

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-01-22
Est. Completion 2028-12
Phase Phase 4

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06311513

The ClinicalTrials.gov registry entry for NCT06311513 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 141 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Anterior Cruciate Ligament Injuries appearing as the primary indexed condition, and to 3 interventions — of which Concentrated Bone Marrow Aspirate Injection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06311513 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Georgia, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06311513 about?

NCT06311513 is a clinical study titled "Concentrated Bone Marrow Aspirate in Revision ACL Reconstruction". The goal of this pilot randomized clinical trial is to look into the efficacy of concentrated bone marrow aspirate (cBMA) in improving post traumatic osteoarthritis (PTOA) symptoms in patients undergoing revision anterior cruciate ligament reconstruction surgery. The main questions it aims to answer...

What is the current status of trial NCT06311513?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2024-01-22. Estimated completion is 2028-12.

What conditions does trial NCT06311513 study?

This clinical trial studies the following conditions: Anterior Cruciate Ligament Injuries, ACL Injury, Bone Marrow Aspirate Concentrate, Post-Traumatic Osteoarthritis of Knee. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06311513?

The interventions under investigation include: Concentrated Bone Marrow Aspirate Injection (BIOLOGICAL), Sham Incision (PROCEDURE), Revision Anterior Cruciate Ligament Reconstruction (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06311513?

This trial is sponsored by Hospital for Special Surgery, New York, which has 141 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06311513 being conducted?

This trial has 2 study locations across Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial